Viromed Medical AG has successfully completed a capital increase, placing 450,000 new registered no-par value shares at EUR 4.50 each, according to a company announcement issued via NEWMEDIAWIRE. The placement generated gross proceeds of approximately EUR 2 million, which the company intends to use to finance its working capital.
The capital increase was executed by partially utilizing the Authorized Capital 2025 and with the exclusion of shareholders' subscription rights. Subject to the registration of the implementation of the capital increase in the commercial register, Viromed's share capital will increase from EUR 21,250,000 by EUR 450,000 to EUR 21,700,000.
The transaction provides Viromed with additional liquidity to support its ongoing operations. The company specializes in the development, manufacture, and distribution of medical products, with a focus on innovative cold plasma technology for medical applications through its wholly owned subsidiary, Viromed Medical GmbH. Since its stock exchange listing in October 2022, Viromed has built a broad customer base in the DACH region and beyond.
The capital increase underscores Viromed's strategy to advance the use of cold plasma technology in medicine and realize corresponding growth potential. The fresh capital is expected to strengthen the company's financial position and enable it to pursue its operational objectives. For investors and industry observers, the move signals management's commitment to funding growth initiatives and maintaining momentum in the medical technology sector.
Further details about the company are available at www.viromed-medical-ag.de. The original release can be viewed on www.newmediawire.com.
